FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma

Annals of Hematology

Volumn 90, Issue 6, 2011, Pages 701-708

  Yu, BaoHua ^a,b   Zhou, XiaoYan ^a,b   Li, BaiZhou ^a,b,c   Xiao, XiuYing ^a,b,d   Yan, ShiYan ^a,b,e   Shi, DaRen ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Center Hospital of Shanghai Xuhui District   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bcl2; DLBCL; FOXP1; Immunohistochemistry; Survival

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CONTROLLED STUDY; EXTRANODAL LARGE CELL LYMPHOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NODAL LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79956146337     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-010-1124-9     Document Type: Article

References (31)

1. Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325-334
2. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006 (Pubitemid 23095683)
3. Sweetenham JW (2005) Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program 252-259
4. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511 (Pubitemid 30082188)
5. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947 (Pubitemid 34651353)
6. Lossos IS, Czerwinski DK, Alizadeh AA et al (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837 (Pubitemid 38917249)
7. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:9991-9996 (Pubitemid 37087056)
8. Barrans SL, Carter I, Owen RG et al (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143 (Pubitemid 34547064)
9. Berglund M, Thunberg U, Amini RM et al (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18:1113-1120 (Pubitemid 41224503)
10. Colomo L, Lopez-Guillermo A, Perales M et al (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101:78-84 (Pubitemid 36025890)
11. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282 (Pubitemid 38029949)
12. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E (2003) Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 9:722-728 (Pubitemid 36182606)
13. Kaufmann E, Knochel W (1996) Five years on the wings of fork head. Mech Dev 57:3-20 (Pubitemid 26197454)
14. Shu W, Yang H, Zhang L, Lu MM, Morrisey EE (2001) Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem 276:27488-27497
15. Banham AH, Beasley N, Campo E et al (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61:8820-8829 (Pubitemid 34013896)
16. ShafferAL, Rosenwald A, Staudt LM(2002) Lymphoidmalignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2:920-932
17. Banham AH, Connors JM, Brown PJ et al (2005) Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072 (Pubitemid 40175755)
18. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS (2004) Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935 (Pubitemid 39434982)
19. Sagaert X, Paepe PD, Libbrecht L et al (2006) Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24:2490-2497 (Pubitemid 46630625)
20. Wlodarska I, Veyt E, De Paepe P et al (2005) FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19:1299-1305 (Pubitemid 41136318)
21. Wang B, Lin D, Li C, Tucker P (2003) Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 278:24259-24268 (Pubitemid 37548575)
22. Brown P, Marafioti T, Kusec R, Banham A (2005) The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J Mol Histol 36:249-256 (Pubitemid 41414402)
23. Iqbal J, Neppalli VT, Wright G et al (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24:961-968 (Pubitemid 46638851)
24. Falini B, Fizzotti M, Pucciarini A et al (2000) A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092 (Pubitemid 30151649)
25. Gaidano G, Carbone A (2000) MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia 14:563-566 (Pubitemid 30195444)
26. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284
27. Kusumoto S, Kobayashi Y, Sekiguchi N et al (2005) Diffuse large b-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "Non-Germinal Center Phenotype". Am J Surg Pathol 29:1067-1073
28. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342-7351 (Pubitemid 33078205)
29. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874 (Pubitemid 34028664)
30. Hoefnagel JJ, MulderMM, Dreef E et al (2006) Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod Pathol 19:1270-1276 (Pubitemid 44268198)
31. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L (2005) Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106:2491-2497 (Pubitemid 41510824)